Breaking News

Monday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Krystal Biotech appoints Andy Orth as CCO » 08:22
05/03/21
05/03
08:22
05/03/21
08:22
KRYS

Krystal Biotech

$79.24 /

-0.9399 (-1.17%)

, ALNY

Alnylam

$140.77 /

+1.36 (+0.98%)

Krystal Biotech (KRYS)…

Krystal Biotech (KRYS) announced the appointment of Andy Orth as Chief Commercial Officer. Mr. Orth was most recently Senior Vice President, Head of US Business at Alnylam Pharmaceuticals (ALNY).

ShowHide Related Items >><<
KRYS Krystal Biotech
$79.24 /

-0.9399 (-1.17%)

ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

KRYS Krystal Biotech
$79.24 /

-0.9399 (-1.17%)

03/01/21 H.C. Wainwright
Krystal Biotech price target raised to $103 from $84 at H.C. Wainwright
03/01/21 William Blair
Krystal Biotech has 'catalyst-rich year ahead,' says William Blair
02/09/21 JonesTrading
Krystal Biotech initiated with a Buy at JonesTrading
01/15/21 Chardan
Krystal Biotech named a 'Top Pick for 2021' at Chardan
ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
KRYS Krystal Biotech
$79.24 /

-0.9399 (-1.17%)

ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

  • 03
    Feb
  • 19
    May
ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

Hot Stocks
Alnylam announces early results from ILLUMINATE-A trial » 07:11
05/03/21
05/03
07:11
05/03/21
07:11
ALNY

Alnylam

$140.77 /

+1.36 (+0.98%)

Alnylam announced early…

Alnylam announced early results on clinical outcome measures from the 12-month analysis of ILLUMINATE-A Phase 3 study of Oxlumo, an RNAi therapeutic targeting hydroxyacid oxidase 1, or HAO1, - the gene encoding glycolate oxidase, or GO - for the treatment of primary hyperoxaluria type 1, or PH1. These data were presented at the American Society of Pediatric Nephrology/Pediatric Academic Societies virtual meeting. As previously reported, treatment with Oxlumo significantly reduced urinary oxalate levels in infants, children and adults with PH1 in the ILLUMINATE-A and ILLUMINATE-B studies. Oxlumo also demonstrated an acceptable safety profile across age groups, with injection site reactions as the most common drug-related adverse reaction. New results from ILLUMINATE-A showed that treatment with Oxlumo for 12 months was associated with evidence of improvements in nephrocalcinosis in one or both kidneys, relative to baseline. Among 24 patients in ILLUMINATE-A who had been treated with lumasiran for 12 months and had valid renal ultrasounds at baseline, 46% of patients experienced improvement in nephrocalcinosis grade relative to baseline, 17% remained stable, and 13% experienced worsening; 25% did not have ultrasounds available at 12 months. Of 14 patients with baseline nephrocalcinosis and available ultrasounds, 79% showed improvement relative to baseline, and of those who improved, 73% improved in both kidneys. Additional data were presented regarding effects on estimated glomerular filtration rate, or eGFR, and kidney stone events.

ShowHide Related Items >><<
ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

ALNY Alnylam
$140.77 /

+1.36 (+0.98%)

Over a week ago
Earnings
Alnylam reports Q1 EPS ($1.64), consensus ($1.75) » 08:11
04/29/21
04/29
08:11
04/29/21
08:11
ALNY

Alnylam

$143.70 /

+2.18 (+1.54%)

Reports Q1 revenue…

Reports Q1 revenue $135.77M consensus $168.74M. "We are extremely pleased with the commercial performance of our marketed products in the first quarter, reflecting strong execution by our global commercial teams. In particular, we achieved steady and continued growth for ONPATTRO with approximately 13% quarterly growth and we observed strong initial demand for OXLUMO in its first full quarter of launch. We also presented positive results from the HELIOS-A Phase 3 study of vutrisiran, and with our recent NDA filing we are one step closer to potentially bringing this transformative medicine to patients. Given the strong pace of enrollment in the HELIOS-B Phase 3 study of vutrisiran, we are announcing today that we expect to complete study enrollment in late 2021, earlier than previously anticipated," said John Maraganore, CEO of Alnylam. "Finally, early in the quarter we launched our new five-year vision, 'Alnylam P5x25,' marking our strategy for a planned transition to a top five biotech company in market capitalization by the end of 2025. With Alnylam P5x25, we aim to deliver transformative medicines for rare and prevalent diseases to patients around the world, while advancing a robust and high-yielding pipeline of first and/or best-in-class clinical programs from our organic product engine, while delivering strong topline growth and profitability within the period."

ShowHide Related Items >><<
ALNY Alnylam
$143.70 /

+2.18 (+1.54%)

ALNY Alnylam
$143.70 /

+2.18 (+1.54%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$143.70 /

+2.18 (+1.54%)

ALNY Alnylam
$143.70 /

+2.18 (+1.54%)

Conference/Events
American Academy of Neurology to hold a virtual meeting » 04:55
04/22/21
04/22
04:55
04/22/21
04:55
ABBV

AbbVie

$110.81 /

+1.78 (+1.63%)

, ABC

AmerisourceBergen

$121.16 /

+0.69 (+0.57%)

, ABT

Abbott

$122.61 /

+2.62 (+2.18%)

, ACAD

Acadia Pharmaceuticals

$21.46 /

+0.67 (+3.22%)

, ALNY

Alnylam

$137.67 /

+2 (+1.47%)

, BIIB

Biogen

$269.13 /

-3.84 (-1.41%)

, BMY

Bristol-Myers

$66.32 /

+0.265 (+0.40%)

, BHVN

Biohaven Pharmaceutical

$75.13 /

+1.5 (+2.04%)

, CPRX

Catalyst Pharmaceuticals

$4.52 /

+0.13 (+2.96%)

, DGX

Quest Diagnostics

$130.08 /

+0.79 (+0.61%)

, DNA

Bought by RHHBY

$94.97 /

+ (+0.00%)

, HZNP

Horizon Therapeutics

$93.52 /

+2.45 (+2.69%)

, LIVN

LivaNova

$83.05 /

+1.63 (+2.00%)

, LLY

Eli Lilly

$191.00 /

+0.45 (+0.24%)

, MDT

Medtronic

$130.19 /

+1.9 (+1.48%)

, NVS

Novartis

$88.67 /

+0.84 (+0.96%)

, NVTA

Invitae

$36.05 /

+1.795 (+5.24%)

, PFE

Pfizer

$39.53 /

+0.5 (+1.28%)

, PTCT

PTC Therapeutics

$45.78 /

-0.545 (-1.18%)

, RETA

Reata Pharmaceuticals

$90.75 /

+1.17 (+1.31%)

, SNY

Sanofi

$52.43 /

+0.44 (+0.85%)

, SUPN

Supernus

$31.37 /

+0.61 (+1.98%)

, TAK

Takeda Pharmaceutical

$16.93 /

+0.095 (+0.56%)

, TEVA

Teva

$10.25 /

+0.135 (+1.33%)

, TGTX

TG Therapeutics

$40.61 /

+0.64 (+1.60%)

, ZGNX

Zogenix

$18.95 /

+0.09 (+0.48%)

, AVDL

Avadel Pharmaceuticals

$8.46 /

+0.265 (+3.24%)

, JNJ

Johnson & Johnson

$166.61 /

+0.16 (+0.10%)

73rd Annual Virtual…

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

TEVA Teva
$10.25 /

+0.135 (+1.33%)

TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

SUPN Supernus
$31.37 /

+0.61 (+1.98%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RETA Reata Pharmaceuticals
$90.75 /

+1.17 (+1.31%)

PTCT PTC Therapeutics
$45.78 /

-0.545 (-1.18%)

PFE Pfizer
$39.53 /

+0.5 (+1.28%)

NVTA Invitae
$36.05 /

+1.795 (+5.24%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

LIVN LivaNova
$83.05 /

+1.63 (+2.00%)

JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

CPRX Catalyst Pharmaceuticals
$4.52 /

+0.13 (+2.96%)

BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

BIIB Biogen
$269.13 /

-3.84 (-1.41%)

BHVN Biohaven Pharmaceutical
$75.13 /

+1.5 (+2.04%)

AVDL Avadel Pharmaceuticals
$8.46 /

+0.265 (+3.24%)

ALNY Alnylam
$137.67 /

+2 (+1.47%)

ACAD Acadia Pharmaceuticals
$21.46 /

+0.67 (+3.22%)

ABT Abbott
$122.61 /

+2.62 (+2.18%)

ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

04/21/21 Citi
Citi sees 'material upside' for AbbVie, Bristol-Myers after Pfizer data
04/21/21 Citi
Citi opens '90-day positive catalyst' on AbbVie, reiterates Buy rating
04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
ABT Abbott
$122.61 /

+2.62 (+2.18%)

04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
03/10/21 Wells Fargo
Wells says Quidel Covid testing comments not a direct read through to Abbott
ACAD Acadia Pharmaceuticals
$21.46 /

+0.67 (+3.22%)

04/07/21 Needham
Acadia price target lowered to $30 from $44 at Needham
04/07/21 H.C. Wainwright
Acadia downgraded to Neutral from Buy at H.C. Wainwright
04/06/21 SVB Leerink
Acadia price target lowered to $31 from $63 at SVB Leerink
04/06/21 Jefferies
Acadia downgraded to Hold at Jefferies after dementia-related psychosis CRL
ALNY Alnylam
$137.67 /

+2 (+1.47%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
BIIB Biogen
$269.13 /

-3.84 (-1.41%)

04/19/21 Jefferies
Biogen 'may have best risk/reward among large caps' in 2021-23, says Jefferies
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

04/21/21 Citi
Citi opens '90-day catalyst watch' on Bristol-Myers, reiterates Buy
04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
BHVN Biohaven Pharmaceutical
$75.13 /

+1.5 (+2.04%)

04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
CPRX Catalyst Pharmaceuticals
$4.52 /

+0.13 (+2.96%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
DNA Bought by RHHBY
$94.97 /

+ (+0.00%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
LIVN LivaNova
$83.05 /

+1.63 (+2.00%)

04/19/21 Piper Sandler
LivaNova HF enrollment milestone a key step toward approval, says Piper Sandler
04/13/21 Piper Sandler
LivaNova price target raised to $92 from $81 at Piper Sandler
03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$130.19 /

+1.9 (+1.48%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
NVS Novartis
$88.67 /

+0.84 (+0.96%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
NVTA Invitae
$36.05 /

+1.795 (+5.24%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
PFE Pfizer
$39.53 /

+0.5 (+1.28%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
PTCT PTC Therapeutics
$45.78 /

-0.545 (-1.18%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RETA Reata Pharmaceuticals
$90.75 /

+1.17 (+1.31%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
SNY Sanofi
$52.43 /

+0.44 (+0.85%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SUPN Supernus
$31.37 /

+0.61 (+1.98%)

04/13/21 Jefferies
Supernus upgraded to Buy after survey work at Jefferies
04/13/21 Jefferies
Supernus upgraded to Buy from Hold at Jefferies
02/03/21 Piper Sandler
Supernus price target raised to $35 from $30 at Piper Sandler
06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
TEVA Teva
$10.25 /

+0.135 (+1.33%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
AVDL Avadel Pharmaceuticals
$8.46 /

+0.265 (+3.24%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

TEVA Teva
$10.25 /

+0.135 (+1.33%)

TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

SUPN Supernus
$31.37 /

+0.61 (+1.98%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RETA Reata Pharmaceuticals
$90.75 /

+1.17 (+1.31%)

PTCT PTC Therapeutics
$45.78 /

-0.545 (-1.18%)

PFE Pfizer
$39.53 /

+0.5 (+1.28%)

NVTA Invitae
$36.05 /

+1.795 (+5.24%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

LIVN LivaNova
$83.05 /

+1.63 (+2.00%)

JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

CPRX Catalyst Pharmaceuticals
$4.52 /

+0.13 (+2.96%)

BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

BIIB Biogen
$269.13 /

-3.84 (-1.41%)

BHVN Biohaven Pharmaceutical
$75.13 /

+1.5 (+2.04%)

AVDL Avadel Pharmaceuticals
$8.46 /

+0.265 (+3.24%)

ALNY Alnylam
$137.67 /

+2 (+1.47%)

ACAD Acadia Pharmaceuticals
$21.46 /

+0.67 (+3.22%)

ABT Abbott
$122.61 /

+2.62 (+2.18%)

ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

  • 16
    Mar
  • 22
    Jan
  • 15
    Dec
  • 02
    Dec
  • 07
    Aug
  • 15
    May
  • 29
    Apr
TEVA Teva
$10.25 /

+0.135 (+1.33%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

PFE Pfizer
$39.53 /

+0.5 (+1.28%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

LIVN LivaNova
$83.05 /

+1.63 (+2.00%)

JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

BIIB Biogen
$269.13 /

-3.84 (-1.41%)

ALNY Alnylam
$137.67 /

+2 (+1.47%)

ABT Abbott
$122.61 /

+2.62 (+2.18%)

ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

TEVA Teva
$10.25 /

+0.135 (+1.33%)

TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

SUPN Supernus
$31.37 /

+0.61 (+1.98%)

SNY Sanofi
$52.43 /

+0.44 (+0.85%)

RETA Reata Pharmaceuticals
$90.75 /

+1.17 (+1.31%)

PTCT PTC Therapeutics
$45.78 /

-0.545 (-1.18%)

PFE Pfizer
$39.53 /

+0.5 (+1.28%)

NVTA Invitae
$36.05 /

+1.795 (+5.24%)

NVS Novartis
$88.67 /

+0.84 (+0.96%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

CPRX Catalyst Pharmaceuticals
$4.52 /

+0.13 (+2.96%)

BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

BIIB Biogen
$269.13 /

-3.84 (-1.41%)

BHVN Biohaven Pharmaceutical
$75.13 /

+1.5 (+2.04%)

AVDL Avadel Pharmaceuticals
$8.46 /

+0.265 (+3.24%)

ACAD Acadia Pharmaceuticals
$21.46 /

+0.67 (+3.22%)

ABT Abbott
$122.61 /

+2.62 (+2.18%)

ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

ZGNX Zogenix
$18.95 /

+0.09 (+0.48%)

TGTX TG Therapeutics
$40.61 /

+0.64 (+1.60%)

TEVA Teva
$10.25 /

+0.135 (+1.33%)

TAK Takeda Pharmaceutical
$16.93 /

+0.095 (+0.56%)

PFE Pfizer
$39.53 /

+0.5 (+1.28%)

NVTA Invitae
$36.05 /

+1.795 (+5.24%)

MDT Medtronic
$130.19 /

+1.9 (+1.48%)

LLY Eli Lilly
$191.00 /

+0.45 (+0.24%)

JNJ Johnson & Johnson
$166.61 /

+0.16 (+0.10%)

HZNP Horizon Therapeutics
$93.52 /

+2.45 (+2.69%)

DGX Quest Diagnostics
$130.08 /

+0.79 (+0.61%)

BMY Bristol-Myers
$66.32 /

+0.265 (+0.40%)

BIIB Biogen
$269.13 /

-3.84 (-1.41%)

ABT Abbott
$122.61 /

+2.62 (+2.18%)

ABC AmerisourceBergen
$121.16 /

+0.69 (+0.57%)

ABBV AbbVie
$110.81 /

+1.78 (+1.63%)

Conference/Events
American Academy of Neurology to hold a virtual meeting » 04:55
04/21/21
04/21
04:55
04/21/21
04:55
ABBV

AbbVie

$109.03 /

+0.43 (+0.40%)

, ABC

AmerisourceBergen

$120.47 /

+0.98 (+0.82%)

, ABT

Abbott

$120.00 /

-4.67 (-3.75%)

, ACAD

Acadia Pharmaceuticals

$20.79 /

+0.01 (+0.05%)

, ALNY

Alnylam

$135.74 /

-1.55 (-1.13%)

, BIIB

Biogen

$272.95 /

+4.05 (+1.51%)

, BMY

Bristol-Myers

$66.06 /

+0.4 (+0.61%)

, BHVN

Biohaven Pharmaceutical

$73.50 /

+1.22 (+1.69%)

, CPRX

Catalyst Pharmaceuticals

$4.39 /

+0.07 (+1.62%)

, DGX

Quest Diagnostics

$129.37 /

-1.69 (-1.29%)

, DNA

Bought by RHHBY

$94.97 /

+ (+0.00%)

, HZNP

Horizon Therapeutics

$91.07 /

+0.88 (+0.98%)

, LIVN

LivaNova

$81.39 /

+0.74 (+0.92%)

, LLY

Eli Lilly

$190.55 /

+0.85 (+0.45%)

, MDT

Medtronic

$128.29 /

+2.13 (+1.69%)

, NVS

Novartis

$87.84 /

-0.52 (-0.59%)

, NVTA

Invitae

$34.25 /

-1.08 (-3.06%)

, PFE

Pfizer

$39.03 /

+0.09 (+0.23%)

, PTCT

PTC Therapeutics

$46.26 /

-1.27 (-2.67%)

, RETA

Reata Pharmaceuticals

$89.28 /

-1.62 (-1.78%)

, SNY

Sanofi

$51.98 /

+0.12 (+0.23%)

, SUPN

Supernus

$30.69 /

-0.24 (-0.78%)

, TAK

Takeda Pharmaceutical

$16.84 /

-0.12 (-0.71%)

, TEVA

Teva

$10.12 /

-0.175 (-1.70%)

, TGTX

TG Therapeutics

$39.95 /

-2.88 (-6.72%)

, ZGNX

Zogenix

$18.79 /

-0.1 (-0.53%)

, AVDL

Avadel Pharmaceuticals

$8.17 /

-0.3 (-3.54%)

, JNJ

Johnson & Johnson

$166.47 /

+3.66 (+2.25%)

73rd Annual Virtual…

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$18.79 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$39.95 /

-2.88 (-6.72%)

TEVA Teva
$10.12 /

-0.175 (-1.70%)

TAK Takeda Pharmaceutical
$16.84 /

-0.12 (-0.71%)

SUPN Supernus
$30.69 /

-0.24 (-0.78%)

SNY Sanofi
$51.98 /

+0.12 (+0.23%)

RETA Reata Pharmaceuticals
$89.28 /

-1.62 (-1.78%)

PTCT PTC Therapeutics
$46.26 /

-1.27 (-2.67%)

PFE Pfizer
$39.03 /

+0.09 (+0.23%)

NVTA Invitae
$34.25 /

-1.08 (-3.06%)

NVS Novartis
$87.84 /

-0.52 (-0.59%)

MDT Medtronic
$128.29 /

+2.13 (+1.69%)

LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

LIVN LivaNova
$81.39 /

+0.74 (+0.92%)

JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

HZNP Horizon Therapeutics
$91.07 /

+0.88 (+0.98%)

DGX Quest Diagnostics
$129.37 /

-1.69 (-1.29%)

CPRX Catalyst Pharmaceuticals
$4.39 /

+0.07 (+1.62%)

BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

BIIB Biogen
$272.95 /

+4.05 (+1.51%)

BHVN Biohaven Pharmaceutical
$73.50 /

+1.22 (+1.69%)

AVDL Avadel Pharmaceuticals
$8.17 /

-0.3 (-3.54%)

ALNY Alnylam
$135.74 /

-1.55 (-1.13%)

ACAD Acadia Pharmaceuticals
$20.79 /

+0.01 (+0.05%)

ABT Abbott
$120.00 /

-4.67 (-3.75%)

ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/17/21 JPMorgan
AbbVie selloff on Rinvoq deal 'appears overdone,' says JPMorgan
ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
ABT Abbott
$120.00 /

-4.67 (-3.75%)

04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
03/10/21 Wells Fargo
Wells says Quidel Covid testing comments not a direct read through to Abbott
ACAD Acadia Pharmaceuticals
$20.79 /

+0.01 (+0.05%)

04/07/21 Needham
Acadia price target lowered to $30 from $44 at Needham
04/07/21 H.C. Wainwright
Acadia downgraded to Neutral from Buy at H.C. Wainwright
04/06/21 SVB Leerink
Acadia price target lowered to $31 from $63 at SVB Leerink
04/06/21 Jefferies
Acadia downgraded to Hold at Jefferies after dementia-related psychosis CRL
ALNY Alnylam
$135.74 /

-1.55 (-1.13%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
BIIB Biogen
$272.95 /

+4.05 (+1.51%)

04/19/21 Jefferies
Biogen 'may have best risk/reward among large caps' in 2021-23, says Jefferies
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
BHVN Biohaven Pharmaceutical
$73.50 /

+1.22 (+1.69%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
CPRX Catalyst Pharmaceuticals
$4.39 /

+0.07 (+1.62%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DGX Quest Diagnostics
$129.37 /

-1.69 (-1.29%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
DNA Bought by RHHBY
$94.97 /

+ (+0.00%)

HZNP Horizon Therapeutics
$91.07 /

+0.88 (+0.98%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
LIVN LivaNova
$81.39 /

+0.74 (+0.92%)

04/19/21 Piper Sandler
LivaNova HF enrollment milestone a key step toward approval, says Piper Sandler
04/13/21 Piper Sandler
LivaNova price target raised to $92 from $81 at Piper Sandler
03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$128.29 /

+2.13 (+1.69%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
NVS Novartis
$87.84 /

-0.52 (-0.59%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
NVTA Invitae
$34.25 /

-1.08 (-3.06%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
PFE Pfizer
$39.03 /

+0.09 (+0.23%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
PTCT PTC Therapeutics
$46.26 /

-1.27 (-2.67%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RETA Reata Pharmaceuticals
$89.28 /

-1.62 (-1.78%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
SNY Sanofi
$51.98 /

+0.12 (+0.23%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SUPN Supernus
$30.69 /

-0.24 (-0.78%)

04/13/21 Jefferies
Supernus upgraded to Buy after survey work at Jefferies
04/13/21 Jefferies
Supernus upgraded to Buy from Hold at Jefferies
02/03/21 Piper Sandler
Supernus price target raised to $35 from $30 at Piper Sandler
06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
TAK Takeda Pharmaceutical
$16.84 /

-0.12 (-0.71%)

04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
TEVA Teva
$10.12 /

-0.175 (-1.70%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
TGTX TG Therapeutics
$39.95 /

-2.88 (-6.72%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
ZGNX Zogenix
$18.79 /

-0.1 (-0.53%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
AVDL Avadel Pharmaceuticals
$8.17 /

-0.3 (-3.54%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
ZGNX Zogenix
$18.79 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$39.95 /

-2.88 (-6.72%)

TEVA Teva
$10.12 /

-0.175 (-1.70%)

TAK Takeda Pharmaceutical
$16.84 /

-0.12 (-0.71%)

SUPN Supernus
$30.69 /

-0.24 (-0.78%)

SNY Sanofi
$51.98 /

+0.12 (+0.23%)

RETA Reata Pharmaceuticals
$89.28 /

-1.62 (-1.78%)

PTCT PTC Therapeutics
$46.26 /

-1.27 (-2.67%)

PFE Pfizer
$39.03 /

+0.09 (+0.23%)

NVTA Invitae
$34.25 /

-1.08 (-3.06%)

NVS Novartis
$87.84 /

-0.52 (-0.59%)

MDT Medtronic
$128.29 /

+2.13 (+1.69%)

LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

LIVN LivaNova
$81.39 /

+0.74 (+0.92%)

JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

HZNP Horizon Therapeutics
$91.07 /

+0.88 (+0.98%)

DGX Quest Diagnostics
$129.37 /

-1.69 (-1.29%)

CPRX Catalyst Pharmaceuticals
$4.39 /

+0.07 (+1.62%)

BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

BIIB Biogen
$272.95 /

+4.05 (+1.51%)

BHVN Biohaven Pharmaceutical
$73.50 /

+1.22 (+1.69%)

AVDL Avadel Pharmaceuticals
$8.17 /

-0.3 (-3.54%)

ALNY Alnylam
$135.74 /

-1.55 (-1.13%)

ACAD Acadia Pharmaceuticals
$20.79 /

+0.01 (+0.05%)

ABT Abbott
$120.00 /

-4.67 (-3.75%)

ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

  • 16
    Mar
  • 22
    Jan
  • 15
    Dec
  • 02
    Dec
  • 07
    Aug
  • 15
    May
  • 29
    Apr
TEVA Teva
$10.12 /

-0.175 (-1.70%)

SNY Sanofi
$51.98 /

+0.12 (+0.23%)

PFE Pfizer
$39.03 /

+0.09 (+0.23%)

NVS Novartis
$87.84 /

-0.52 (-0.59%)

LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

LIVN LivaNova
$81.39 /

+0.74 (+0.92%)

JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

BIIB Biogen
$272.95 /

+4.05 (+1.51%)

ALNY Alnylam
$135.74 /

-1.55 (-1.13%)

ABT Abbott
$120.00 /

-4.67 (-3.75%)

ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

ZGNX Zogenix
$18.79 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$39.95 /

-2.88 (-6.72%)

TEVA Teva
$10.12 /

-0.175 (-1.70%)

TAK Takeda Pharmaceutical
$16.84 /

-0.12 (-0.71%)

SUPN Supernus
$30.69 /

-0.24 (-0.78%)

SNY Sanofi
$51.98 /

+0.12 (+0.23%)

RETA Reata Pharmaceuticals
$89.28 /

-1.62 (-1.78%)

PTCT PTC Therapeutics
$46.26 /

-1.27 (-2.67%)

PFE Pfizer
$39.03 /

+0.09 (+0.23%)

NVTA Invitae
$34.25 /

-1.08 (-3.06%)

NVS Novartis
$87.84 /

-0.52 (-0.59%)

LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

HZNP Horizon Therapeutics
$91.07 /

+0.88 (+0.98%)

DGX Quest Diagnostics
$129.37 /

-1.69 (-1.29%)

CPRX Catalyst Pharmaceuticals
$4.39 /

+0.07 (+1.62%)

BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

BIIB Biogen
$272.95 /

+4.05 (+1.51%)

BHVN Biohaven Pharmaceutical
$73.50 /

+1.22 (+1.69%)

AVDL Avadel Pharmaceuticals
$8.17 /

-0.3 (-3.54%)

ACAD Acadia Pharmaceuticals
$20.79 /

+0.01 (+0.05%)

ABT Abbott
$120.00 /

-4.67 (-3.75%)

ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

ZGNX Zogenix
$18.79 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$39.95 /

-2.88 (-6.72%)

TEVA Teva
$10.12 /

-0.175 (-1.70%)

TAK Takeda Pharmaceutical
$16.84 /

-0.12 (-0.71%)

PFE Pfizer
$39.03 /

+0.09 (+0.23%)

NVTA Invitae
$34.25 /

-1.08 (-3.06%)

MDT Medtronic
$128.29 /

+2.13 (+1.69%)

LLY Eli Lilly
$190.55 /

+0.85 (+0.45%)

JNJ Johnson & Johnson
$166.47 /

+3.66 (+2.25%)

HZNP Horizon Therapeutics
$91.07 /

+0.88 (+0.98%)

DGX Quest Diagnostics
$129.37 /

-1.69 (-1.29%)

BMY Bristol-Myers
$66.06 /

+0.4 (+0.61%)

BIIB Biogen
$272.95 /

+4.05 (+1.51%)

ABT Abbott
$120.00 /

-4.67 (-3.75%)

ABC AmerisourceBergen
$120.47 /

+0.98 (+0.82%)

ABBV AbbVie
$109.03 /

+0.43 (+0.40%)

Conference/Events
American Academy of Neurology to hold a virtual meeting » 04:55
04/20/21
04/20
04:55
04/20/21
04:55
ABBV

AbbVie

$108.66 /

+0.73 (+0.68%)

, ABC

AmerisourceBergen

$119.49 /

-0.02 (-0.02%)

, ABT

Abbott

$124.67 /

+0.3 (+0.24%)

, ACAD

Acadia Pharmaceuticals

$20.78 /

-0.39 (-1.84%)

, ALNY

Alnylam

$137.25 /

-1.535 (-1.11%)

, BIIB

Biogen

$268.99 /

-1.23 (-0.46%)

, BMY

Bristol-Myers

$65.66 /

+0.2 (+0.31%)

, BHVN

Biohaven Pharmaceutical

$72.23 /

-2.135 (-2.87%)

, CPRX

Catalyst Pharmaceuticals

$4.32 /

-0.115 (-2.59%)

, DGX

Quest Diagnostics

$130.97 /

+0.86 (+0.66%)

, DNA

Bought by RHHBY

$94.97 /

+ (+0.00%)

, HZNP

Horizon Therapeutics

$90.26 /

-3.06 (-3.28%)

, LIVN

LivaNova

$80.65 /

-0.7 (-0.86%)

, LLY

Eli Lilly

$189.86 /

+0.58 (+0.31%)

, MDT

Medtronic

$126.16 /

+0.25 (+0.20%)

, NVS

Novartis

$88.36 /

+0.335 (+0.38%)

, NVTA

Invitae

$35.34 /

-2.31 (-6.14%)

, PFE

Pfizer

$38.94 /

+0.37 (+0.96%)

, PTCT

PTC Therapeutics

$47.53 /

-1.01 (-2.08%)

, RETA

Reata Pharmaceuticals

$91.38 /

+0.55 (+0.61%)

, SNY

Sanofi

$51.86 /

+0.56 (+1.09%)

, SUPN

Supernus

$30.93 /

-0.82 (-2.58%)

, TAK

Takeda Pharmaceutical

$16.95 /

-0.115 (-0.67%)

, TEVA

Teva

$10.29 /

-0.46 (-4.28%)

, TGTX

TG Therapeutics

$42.83 /

-1.88 (-4.20%)

, ZGNX

Zogenix

$18.89 /

-0.1 (-0.53%)

, AVDL

Avadel Pharmaceuticals

$8.47 /

-0.18 (-2.08%)

, JNJ

Johnson & Johnson

$162.98 /

+0.83 (+0.51%)

73rd Annual Virtual…

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$18.89 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$42.83 /

-1.88 (-4.20%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

TAK Takeda Pharmaceutical
$16.95 /

-0.115 (-0.67%)

SUPN Supernus
$30.93 /

-0.82 (-2.58%)

SNY Sanofi
$51.86 /

+0.56 (+1.09%)

RETA Reata Pharmaceuticals
$91.38 /

+0.55 (+0.61%)

PTCT PTC Therapeutics
$47.53 /

-1.01 (-2.08%)

PFE Pfizer
$38.94 /

+0.37 (+0.96%)

NVTA Invitae
$35.34 /

-2.31 (-6.14%)

NVS Novartis
$88.36 /

+0.335 (+0.38%)

MDT Medtronic
$126.16 /

+0.25 (+0.20%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

LIVN LivaNova
$80.65 /

-0.7 (-0.86%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

HZNP Horizon Therapeutics
$90.26 /

-3.06 (-3.28%)

DGX Quest Diagnostics
$130.97 /

+0.86 (+0.66%)

CPRX Catalyst Pharmaceuticals
$4.32 /

-0.115 (-2.59%)

BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

BIIB Biogen
$268.99 /

-1.23 (-0.46%)

BHVN Biohaven Pharmaceutical
$72.23 /

-2.135 (-2.87%)

AVDL Avadel Pharmaceuticals
$8.47 /

-0.18 (-2.08%)

ALNY Alnylam
$137.25 /

-1.535 (-1.11%)

ACAD Acadia Pharmaceuticals
$20.78 /

-0.39 (-1.84%)

ABT Abbott
$124.67 /

+0.3 (+0.24%)

ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/17/21 JPMorgan
AbbVie selloff on Rinvoq deal 'appears overdone,' says JPMorgan
ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
ABT Abbott
$124.67 /

+0.3 (+0.24%)

04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
03/10/21 Wells Fargo
Wells says Quidel Covid testing comments not a direct read through to Abbott
ACAD Acadia Pharmaceuticals
$20.78 /

-0.39 (-1.84%)

04/07/21 Needham
Acadia price target lowered to $30 from $44 at Needham
04/07/21 H.C. Wainwright
Acadia downgraded to Neutral from Buy at H.C. Wainwright
04/06/21 SVB Leerink
Acadia price target lowered to $31 from $63 at SVB Leerink
04/06/21 Jefferies
Acadia downgraded to Hold at Jefferies after dementia-related psychosis CRL
ALNY Alnylam
$137.25 /

-1.535 (-1.11%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
BIIB Biogen
$268.99 /

-1.23 (-0.46%)

04/19/21 Jefferies
Biogen 'may have best risk/reward among large caps' in 2021-23, says Jefferies
04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
BHVN Biohaven Pharmaceutical
$72.23 /

-2.135 (-2.87%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
CPRX Catalyst Pharmaceuticals
$4.32 /

-0.115 (-2.59%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DGX Quest Diagnostics
$130.97 /

+0.86 (+0.66%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
DNA Bought by RHHBY
$94.97 /

+ (+0.00%)

HZNP Horizon Therapeutics
$90.26 /

-3.06 (-3.28%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
LIVN LivaNova
$80.65 /

-0.7 (-0.86%)

04/19/21 Piper Sandler
LivaNova HF enrollment milestone a key step toward approval, says Piper Sandler
04/13/21 Piper Sandler
LivaNova price target raised to $92 from $81 at Piper Sandler
03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$126.16 /

+0.25 (+0.20%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
NVS Novartis
$88.36 /

+0.335 (+0.38%)

04/19/21 UBS
Novartis price target raised to CHF 96 from CHF 95 at UBS
04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
NVTA Invitae
$35.34 /

-2.31 (-6.14%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
PFE Pfizer
$38.94 /

+0.37 (+0.96%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
PTCT PTC Therapeutics
$47.53 /

-1.01 (-2.08%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RETA Reata Pharmaceuticals
$91.38 /

+0.55 (+0.61%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
SNY Sanofi
$51.86 /

+0.56 (+1.09%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SUPN Supernus
$30.93 /

-0.82 (-2.58%)

04/13/21 Jefferies
Supernus upgraded to Buy after survey work at Jefferies
04/13/21 Jefferies
Supernus upgraded to Buy from Hold at Jefferies
02/03/21 Piper Sandler
Supernus price target raised to $35 from $30 at Piper Sandler
06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
TAK Takeda Pharmaceutical
$16.95 /

-0.115 (-0.67%)

04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
TEVA Teva
$10.29 /

-0.46 (-4.28%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
TGTX TG Therapeutics
$42.83 /

-1.88 (-4.20%)

04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
03/04/21 B. Riley
TG Therapeutics price target lowered to $91 from $95 at B. Riley Securities
02/09/21 B. Riley
TG Therapeutics price target raised to $95 from $90 at B. Riley Securities
ZGNX Zogenix
$18.89 /

-0.1 (-0.53%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
AVDL Avadel Pharmaceuticals
$8.47 /

-0.18 (-2.08%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
ZGNX Zogenix
$18.89 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$42.83 /

-1.88 (-4.20%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

TAK Takeda Pharmaceutical
$16.95 /

-0.115 (-0.67%)

SUPN Supernus
$30.93 /

-0.82 (-2.58%)

SNY Sanofi
$51.86 /

+0.56 (+1.09%)

RETA Reata Pharmaceuticals
$91.38 /

+0.55 (+0.61%)

PTCT PTC Therapeutics
$47.53 /

-1.01 (-2.08%)

PFE Pfizer
$38.94 /

+0.37 (+0.96%)

NVTA Invitae
$35.34 /

-2.31 (-6.14%)

NVS Novartis
$88.36 /

+0.335 (+0.38%)

MDT Medtronic
$126.16 /

+0.25 (+0.20%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

LIVN LivaNova
$80.65 /

-0.7 (-0.86%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

HZNP Horizon Therapeutics
$90.26 /

-3.06 (-3.28%)

DGX Quest Diagnostics
$130.97 /

+0.86 (+0.66%)

CPRX Catalyst Pharmaceuticals
$4.32 /

-0.115 (-2.59%)

BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

BIIB Biogen
$268.99 /

-1.23 (-0.46%)

BHVN Biohaven Pharmaceutical
$72.23 /

-2.135 (-2.87%)

AVDL Avadel Pharmaceuticals
$8.47 /

-0.18 (-2.08%)

ALNY Alnylam
$137.25 /

-1.535 (-1.11%)

ACAD Acadia Pharmaceuticals
$20.78 /

-0.39 (-1.84%)

ABT Abbott
$124.67 /

+0.3 (+0.24%)

ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

  • 16
    Mar
  • 22
    Jan
  • 15
    Dec
  • 02
    Dec
  • 07
    Aug
  • 15
    May
  • 29
    Apr
TEVA Teva
$10.29 /

-0.46 (-4.28%)

SNY Sanofi
$51.86 /

+0.56 (+1.09%)

PFE Pfizer
$38.94 /

+0.37 (+0.96%)

NVS Novartis
$88.36 /

+0.335 (+0.38%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

LIVN LivaNova
$80.65 /

-0.7 (-0.86%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

BIIB Biogen
$268.99 /

-1.23 (-0.46%)

ALNY Alnylam
$137.25 /

-1.535 (-1.11%)

ABT Abbott
$124.67 /

+0.3 (+0.24%)

ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

ZGNX Zogenix
$18.89 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$42.83 /

-1.88 (-4.20%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

TAK Takeda Pharmaceutical
$16.95 /

-0.115 (-0.67%)

SUPN Supernus
$30.93 /

-0.82 (-2.58%)

SNY Sanofi
$51.86 /

+0.56 (+1.09%)

RETA Reata Pharmaceuticals
$91.38 /

+0.55 (+0.61%)

PTCT PTC Therapeutics
$47.53 /

-1.01 (-2.08%)

PFE Pfizer
$38.94 /

+0.37 (+0.96%)

NVTA Invitae
$35.34 /

-2.31 (-6.14%)

NVS Novartis
$88.36 /

+0.335 (+0.38%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

HZNP Horizon Therapeutics
$90.26 /

-3.06 (-3.28%)

DGX Quest Diagnostics
$130.97 /

+0.86 (+0.66%)

CPRX Catalyst Pharmaceuticals
$4.32 /

-0.115 (-2.59%)

BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

BIIB Biogen
$268.99 /

-1.23 (-0.46%)

BHVN Biohaven Pharmaceutical
$72.23 /

-2.135 (-2.87%)

AVDL Avadel Pharmaceuticals
$8.47 /

-0.18 (-2.08%)

ACAD Acadia Pharmaceuticals
$20.78 /

-0.39 (-1.84%)

ABT Abbott
$124.67 /

+0.3 (+0.24%)

ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

ZGNX Zogenix
$18.89 /

-0.1 (-0.53%)

TGTX TG Therapeutics
$42.83 /

-1.88 (-4.20%)

TEVA Teva
$10.29 /

-0.46 (-4.28%)

TAK Takeda Pharmaceutical
$16.95 /

-0.115 (-0.67%)

PFE Pfizer
$38.94 /

+0.37 (+0.96%)

NVTA Invitae
$35.34 /

-2.31 (-6.14%)

MDT Medtronic
$126.16 /

+0.25 (+0.20%)

LLY Eli Lilly
$189.86 /

+0.58 (+0.31%)

JNJ Johnson & Johnson
$162.98 /

+0.83 (+0.51%)

HZNP Horizon Therapeutics
$90.26 /

-3.06 (-3.28%)

DGX Quest Diagnostics
$130.97 /

+0.86 (+0.66%)

BMY Bristol-Myers
$65.66 /

+0.2 (+0.31%)

BIIB Biogen
$268.99 /

-1.23 (-0.46%)

ABT Abbott
$124.67 /

+0.3 (+0.24%)

ABC AmerisourceBergen
$119.49 /

-0.02 (-0.02%)

ABBV AbbVie
$108.66 /

+0.73 (+0.68%)

Conference/Events
Alnylam to host conference call » 15:55
04/19/21
04/19
15:55
04/19/21
15:55
ALNY

Alnylam

$137.01 /

-1.775 (-1.28%)

Management holds a…

Management holds a conference call to discuss the full 9-month results from the HELIOS-A Phase 3 clinical trial on April 19 at 4 pm. Webcast Link

ShowHide Related Items >><<
ALNY Alnylam
$137.01 /

-1.775 (-1.28%)

ALNY Alnylam
$137.01 /

-1.775 (-1.28%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$137.01 /

-1.775 (-1.28%)

ALNY Alnylam
$137.01 /

-1.775 (-1.28%)

Hot Stocks
Alnylam announces full 'positive' results from HELIOS-A Phase 3 study » 14:02
04/19/21
04/19
14:02
04/19/21
14:02
ALNY

Alnylam

$137.04 /

-1.745 (-1.26%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals announced full "positive" results from the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, which met its primary and both secondary endpoints at nine months in patients with hereditary ATTR amyloidosis with polyneuropathy. The results were presented in an oral session at the 2021 American Academy of Neurology, or AAN, Virtual Annual Meeting. The 9-month results achieved the study's primary endpoint, with vutrisiran showing improvement in the mean change from baseline in the modified Neuropathy Impairment Score as compared to external placebo data from the APOLLO Phase 3 study of patisiran. At 9 months vutrisiran also met all secondary endpoints, demonstrating improvement in quality of life as assessed by the Norfolk Quality of Life Questionnaire-Diabetic Neuropathy instrument and improvement in gait speed as assessed by the timed 10-meter walk test, both compared to the external placebo group. The majority of patients experienced improvement in neuropathy and in quality of life, both relative to baseline, showing the potential for vutrisiran to reverse polyneuropathy manifestations of hATTR amyloidosis. Vutrisiran also demonstrated an "encouraging safety profile" with no drug-related discontinuations or deaths, the company said. Based on these "positive data," Alnylam has submitted a New Drug Application with the U.S. Food and Drug Administration for the approval of vutrisiran for the treatment of the polyneuropathy of hATTR amyloidosis in adults, the company stated.

ShowHide Related Items >><<
ALNY Alnylam
$137.04 /

-1.745 (-1.26%)

ALNY Alnylam
$137.04 /

-1.745 (-1.26%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$137.04 /

-1.745 (-1.26%)

ALNY Alnylam
$137.04 /

-1.745 (-1.26%)

Conference/Events
American Academy of Neurology to hold a virtual meeting » 09:24
04/19/21
04/19
09:24
04/19/21
09:24
ABBV

AbbVie

$107.93 /

+1.05 (+0.98%)

, ABC

AmerisourceBergen

$119.62 /

+0.55 (+0.46%)

, ABT

Abbott

$124.37 /

+0.4 (+0.32%)

, ACAD

Acadia Pharmaceuticals

$21.17 /

-0.02 (-0.09%)

, ALNY

Alnylam

$138.69 /

-0.23 (-0.17%)

, BIIB

Biogen

$270.07 /

-0.66 (-0.24%)

, BMY

Bristol-Myers

$65.46 /

+1.02 (+1.58%)

, BHVN

Biohaven Pharmaceutical

$74.37 /

-1.435 (-1.89%)

, CPRX

Catalyst Pharmaceuticals

$4.44 /

-0.02 (-0.45%)

, DGX

Quest Diagnostics

$130.09 /

+0.86 (+0.67%)

, DNA

Bought by RHHBY

$94.97 /

+ (+0.00%)

, HZNP

Horizon Therapeutics

$93.25 /

-0.32 (-0.34%)

, LIVN

LivaNova

$81.37 /

-1.46 (-1.76%)

, LLY

Eli Lilly

$189.25 /

+3.28 (+1.76%)

, MDT

Medtronic

$125.91 /

+0.06 (+0.05%)

, NVS

Novartis

$88.02 /

+0.81 (+0.93%)

, NVTA

Invitae

$37.65 /

-1.47 (-3.76%)

, PFE

Pfizer

$38.57 /

+0.96 (+2.55%)

, PTCT

PTC Therapeutics

$48.48 /

+0.33 (+0.69%)

, RETA

Reata Pharmaceuticals

$90.83 /

-1.29 (-1.40%)

, SNY

Sanofi

$51.29 /

+0.63 (+1.24%)

, SUPN

Supernus

$31.72 /

-0.09 (-0.28%)

, TAK

Takeda Pharmaceutical

$17.08 /

-0.13 (-0.76%)

, TEVA

Teva

$10.75 /

-0.08 (-0.74%)

, TGTX

TG Therapeutics

$44.79 /

-1.05 (-2.29%)

, ZGNX

Zogenix

$19.00 /

-0.65 (-3.31%)

, AVDL

Avadel Pharmaceuticals

$8.65 /

+0.09 (+1.05%)

, JNJ

Johnson & Johnson

$162.24 /

+1.74 (+1.08%)

73rd Annual Virtual…

73rd Annual Virtual Meeting of AAN will be held on April 17-22. Webcast Link

ShowHide Related Items >><<
ZGNX Zogenix
$19.00 /

-0.65 (-3.31%)

TGTX TG Therapeutics
$44.79 /

-1.05 (-2.29%)

TEVA Teva
$10.75 /

-0.08 (-0.74%)

TAK Takeda Pharmaceutical
$17.08 /

-0.13 (-0.76%)

SUPN Supernus
$31.72 /

-0.09 (-0.28%)

SNY Sanofi
$51.29 /

+0.63 (+1.24%)

RETA Reata Pharmaceuticals
$90.83 /

-1.29 (-1.40%)

PTCT PTC Therapeutics
$48.48 /

+0.33 (+0.69%)

PFE Pfizer
$38.57 /

+0.96 (+2.55%)

NVTA Invitae
$37.65 /

-1.47 (-3.76%)

NVS Novartis
$88.02 /

+0.81 (+0.93%)

MDT Medtronic
$125.91 /

+0.06 (+0.05%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LIVN LivaNova
$81.37 /

-1.46 (-1.76%)

JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

HZNP Horizon Therapeutics
$93.25 /

-0.32 (-0.34%)

DGX Quest Diagnostics
$130.09 /

+0.86 (+0.67%)

CPRX Catalyst Pharmaceuticals
$4.44 /

-0.02 (-0.45%)

BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

BIIB Biogen
$270.07 /

-0.66 (-0.24%)

BHVN Biohaven Pharmaceutical
$74.37 /

-1.435 (-1.89%)

AVDL Avadel Pharmaceuticals
$8.65 /

+0.09 (+1.05%)

ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

ACAD Acadia Pharmaceuticals
$21.17 /

-0.02 (-0.09%)

ABT Abbott
$124.37 /

+0.4 (+0.32%)

ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

04/06/21 RBC Capital
AbbVie transferred with an Outperform at RBC Capital
04/01/21 Piper Sandler
Integra to benefit from FDA safety communication, says Piper Sandler
04/01/21 Piper Sandler
Piper migraine survey bearish for Amgen, bullish for Biohaven
03/17/21 JPMorgan
AbbVie selloff on Rinvoq deal 'appears overdone,' says JPMorgan
ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

03/09/21 Baird
AmerisourceBergen remains top pick following results, says Baird
02/09/21 Mizuho
AmerisourceBergen price target raised to $114 from $104 at Mizuho
02/08/21 Cowen
AmerisourceBergen price target raised to $150 from $145 at Cowen
02/04/21 Evercore ISI
AmerisourceBergen upgraded to Outperform after Q1 report at Evercore ISI
ABT Abbott
$124.37 /

+0.4 (+0.32%)

04/15/21 Atlantic Equities
Atlantic Equities starts Abbott at Neutral
04/15/21 Atlantic Equities
Abbott initiated with a Neutral at Atlantic Equities
03/16/21 Piper Sandler
Abbott study challenging Abiomed's Impella halted, says Piper Sandler
03/10/21 Wells Fargo
Wells says Quidel Covid testing comments not a direct read through to Abbott
ACAD Acadia Pharmaceuticals
$21.17 /

-0.02 (-0.09%)

04/07/21 Needham
Acadia price target lowered to $30 from $44 at Needham
04/07/21 H.C. Wainwright
Acadia downgraded to Neutral from Buy at H.C. Wainwright
04/06/21 SVB Leerink
Acadia price target lowered to $31 from $63 at SVB Leerink
04/06/21 Jefferies
Acadia downgraded to Hold at Jefferies after dementia-related psychosis CRL
ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
BIIB Biogen
$270.07 /

-0.66 (-0.24%)

04/13/21 Roth Capital
Roth Capital sees Applied Genetic's XLRS licensing as vote of confidence
04/12/21 Oppenheimer
Sage Therapeutics data support 'enthusiasm' for SAGE-324 in ET, says Oppenheimer
04/12/21 Wedbush
Biogen price target raised to $245 from $236 at Wedbush
03/25/21 Piper Sandler
Piper says Biogen Tecfidera patents could change thesis, but sees unknowns
BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

04/13/21 Truist
Bristol-Myers upgraded to Buy at Truist on improving pipeline asset visibility
04/13/21 Truist
Bristol-Myers upgraded to Buy from Hold at Truist
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/08/21 BofA
Gartner added to US 1 List, Bristol-Myers removed at BofA
BHVN Biohaven Pharmaceutical
$74.37 /

-1.435 (-1.89%)

03/11/21
Fly Intel: Top five analyst initiations
03/11/21 UBS
Biohaven Pharmaceutical initiated with a Buy at UBS
03/02/21 Mizuho
Biohaven Pharmaceutical price target raised to $103 from $93 at Mizuho
CPRX Catalyst Pharmaceuticals
$4.44 /

-0.02 (-0.45%)

03/16/21 Piper Sandler
Catalyst business continues to generate cash flow, says Piper Sandler
01/07/21 Piper Sandler
Piper says Catalyst's Firdapse commercial business performing as expected
01/06/21 Piper Sandler
Catalyst Firdapse commercial business performing as expected, says Piper Sandler
11/10/20 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $5.50 from $6 at Piper Sandler
DGX Quest Diagnostics
$130.09 /

+0.86 (+0.67%)

03/12/21 Baird
Quest Diagnostics downgraded to Neutral from Outperform at Baird
01/29/21 Citi
Quest Diagnostics price target raised to $158 from $151 at Citi
12/17/20 Morgan Stanley
Morgan Stanley cuts Quest Diagnostics to Equal Weight ahead of 2022 slowdown
12/17/20 Morgan Stanley
Quest Diagnostics downgraded to Equal Weight from Overweight at Morgan Stanley
DNA Bought by RHHBY
$94.97 /

+ (+0.00%)

HZNP Horizon Therapeutics
$93.25 /

-0.32 (-0.34%)

03/25/21 Guggenheim
Horizon Therapeutics price target raised to $120 from $115 at Guggenheim
03/22/21
Fly Intel: Top five analyst initiations
03/22/21 Morgan Stanley
Horizon Therapeutics resumed with an Overweight at Morgan Stanley
03/18/21 Citi
Horizon Therapeutics price target raised to $120 from $116 at Citi
LIVN LivaNova
$81.37 /

-1.46 (-1.76%)

04/13/21 Piper Sandler
LivaNova price target raised to $92 from $81 at Piper Sandler
03/03/21
Fly Intel: Top five analyst downgrades
03/03/21 Berenberg
Berenberg cuts LivaNova EPS forecasts on investments, downgrades to Hold
03/03/21 Berenberg
LivaNova downgraded to Hold from Buy at Berenberg
LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

04/12/21 Benchmark
Benchmark sees full FDA approval of Regeneron's REGEN-COV coming
04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
MDT Medtronic
$125.91 /

+0.06 (+0.05%)

04/15/21 Atlantic Equities
Atlantic Equities starts Medtronic at Overweight
04/15/21 Atlantic Equities
Medtronic initiated with an Overweight at Atlantic Equities
04/05/21 Citi
Citi opens positive catalyst watches on four medical supply stocks
02/24/21 Cowen
Medtronic price target raised to $135 from $120 at Cowen
NVS Novartis
$88.02 /

+0.81 (+0.93%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/23/21 Societe Generale
Novartis price target raised to CHF 107 from CHF 104 at Societe Generale
03/22/21 Bernstein
Novartis initiated with a Market Perform at Bernstein
03/10/21
Fly Intel: Top five analyst downgrades
NVTA Invitae
$37.65 /

-1.47 (-3.76%)

04/05/21 Oppenheimer
Oppenheimer upgrades Invitae on valuation, sees potential high $50s stock
04/05/21 Oppenheimer
Invitae upgraded to Outperform from Perform at Oppenheimer
02/18/21 Ladenburg
Invitae upgraded to Buy with $58 price target at Ladenburg
02/18/21 Ladenburg
Invitae upgraded to Buy from Neutral at Ladenburg
PFE Pfizer
$38.57 /

+0.96 (+2.55%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
PTCT PTC Therapeutics
$48.48 /

+0.33 (+0.69%)

03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform at RBC Capital on valuation
03/29/21 RBC Capital
PTC Therapeutics upgraded to Sector Perform from Underperform at RBC Capital
02/26/21 Cantor Fitzgerald
PTC Therapeutics price target lowered to $75 from $81 at Cantor Fitzgerald
02/12/21 BofA
PTC Therapeutics downgraded to Neutral from Buy at BofA
RETA Reata Pharmaceuticals
$90.83 /

-1.29 (-1.40%)

11/25/20 Citi
Reata Pharmaceuticals price target lowered to $234 from $260 at Citi
11/10/20 Cantor Fitzgerald
Reata Pharmaceuticals price target raised to $220 from $169 at Cantor Fitzgerald
11/10/20 Citi
Reata Pharmaceuticals price target raised to $260 from $244 at Citi
08/11/20 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $169 from $275 at Cantor Fitzgerald
SNY Sanofi
$51.29 /

+0.63 (+1.24%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
SUPN Supernus
$31.72 /

-0.09 (-0.28%)

04/13/21 Jefferies
Supernus upgraded to Buy after survey work at Jefferies
04/13/21 Jefferies
Supernus upgraded to Buy from Hold at Jefferies
02/03/21 Piper Sandler
Supernus price target raised to $35 from $30 at Piper Sandler
06/16/20 Piper Sandler
Supernus upgraded to Overweight from Neutral at Piper Sandler
TAK Takeda Pharmaceutical
$17.08 /

-0.13 (-0.76%)

04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral on R&D investments at JPMorgan
04/19/21 JPMorgan
Takeda Pharmaceutical downgraded to Neutral from Overweight at JPMorgan
04/15/21 Oppenheimer
Molecular Templates price target lowered to $13 from $18 at Oppenheimer
04/05/21
Fly Intel: Top five analyst downgrades
TEVA Teva
$10.75 /

-0.08 (-0.74%)

04/06/21 RBC Capital
Teva transferred with a Sector Perform at RBC Capital
01/26/21 Piper Sandler
Amarin in 'strong position' against Health Net, says Piper Sandler
12/21/20 Gabelli
Teva named 'Best Idea for 2021' at Gabelli
11/27/20 H.C. Wainwright
Corcept Therapeutics price target raised to $32 from $22 at H.C. Wainwright
TGTX TG Therapeutics
$44.79 /

-1.05 (-2.29%)

04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
03/04/21 B. Riley
TG Therapeutics price target lowered to $91 from $95 at B. Riley Securities
02/09/21 B. Riley
TG Therapeutics price target raised to $95 from $90 at B. Riley Securities
ZGNX Zogenix
$19.00 /

-0.65 (-3.31%)

04/06/21 Evercore ISI
Evercore starts 'compelling' Arena spinoff Longboard at Outperform
04/06/21 Citi
Longboard Pharmaceuticals initiated with a Buy at Citi
02/03/21 Mizuho
Jazz deal for GW Pharma has positive read through to Zogenix, says Mizuho
12/04/20 Mizuho
Zogenix collaboration step in right direction, says Mizuho
AVDL Avadel Pharmaceuticals
$8.65 /

+0.09 (+1.05%)

03/10/21 H.C. Wainwright
Avadel Pharmaceuticals price target raised to $17 from $15 at H.C. Wainwright
01/25/21 Craig-Hallum
Avadel Pharmaceuticals assumed with a Buy rating at Craig-Hallum
08/28/20 Oppenheimer
Uwarranted pressure creates buying opportunity for Avadel, says Oppenheimer
08/28/20 SVB Leerink
Avadel selloff on Jazz competition worries overdone, says SVB Leerink
JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

04/19/21 Chardan
Chardan sees J&J moving forward with Emergent if observations are minor
04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
ZGNX Zogenix
$19.00 /

-0.65 (-3.31%)

TGTX TG Therapeutics
$44.79 /

-1.05 (-2.29%)

TEVA Teva
$10.75 /

-0.08 (-0.74%)

TAK Takeda Pharmaceutical
$17.08 /

-0.13 (-0.76%)

SUPN Supernus
$31.72 /

-0.09 (-0.28%)

SNY Sanofi
$51.29 /

+0.63 (+1.24%)

RETA Reata Pharmaceuticals
$90.83 /

-1.29 (-1.40%)

PTCT PTC Therapeutics
$48.48 /

+0.33 (+0.69%)

PFE Pfizer
$38.57 /

+0.96 (+2.55%)

NVTA Invitae
$37.65 /

-1.47 (-3.76%)

NVS Novartis
$88.02 /

+0.81 (+0.93%)

MDT Medtronic
$125.91 /

+0.06 (+0.05%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LIVN LivaNova
$81.37 /

-1.46 (-1.76%)

JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

HZNP Horizon Therapeutics
$93.25 /

-0.32 (-0.34%)

DGX Quest Diagnostics
$130.09 /

+0.86 (+0.67%)

CPRX Catalyst Pharmaceuticals
$4.44 /

-0.02 (-0.45%)

BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

BIIB Biogen
$270.07 /

-0.66 (-0.24%)

BHVN Biohaven Pharmaceutical
$74.37 /

-1.435 (-1.89%)

AVDL Avadel Pharmaceuticals
$8.65 /

+0.09 (+1.05%)

ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

ACAD Acadia Pharmaceuticals
$21.17 /

-0.02 (-0.09%)

ABT Abbott
$124.37 /

+0.4 (+0.32%)

ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

  • 16
    Mar
  • 22
    Jan
  • 15
    Dec
  • 02
    Dec
  • 07
    Aug
  • 15
    May
  • 29
    Apr
TEVA Teva
$10.75 /

-0.08 (-0.74%)

SNY Sanofi
$51.29 /

+0.63 (+1.24%)

PFE Pfizer
$38.57 /

+0.96 (+2.55%)

NVS Novartis
$88.02 /

+0.81 (+0.93%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

LIVN LivaNova
$81.37 /

-1.46 (-1.76%)

JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

BIIB Biogen
$270.07 /

-0.66 (-0.24%)

ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

ABT Abbott
$124.37 /

+0.4 (+0.32%)

ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

ZGNX Zogenix
$19.00 /

-0.65 (-3.31%)

TGTX TG Therapeutics
$44.79 /

-1.05 (-2.29%)

TEVA Teva
$10.75 /

-0.08 (-0.74%)

TAK Takeda Pharmaceutical
$17.08 /

-0.13 (-0.76%)

SUPN Supernus
$31.72 /

-0.09 (-0.28%)

SNY Sanofi
$51.29 /

+0.63 (+1.24%)

RETA Reata Pharmaceuticals
$90.83 /

-1.29 (-1.40%)

PTCT PTC Therapeutics
$48.48 /

+0.33 (+0.69%)

PFE Pfizer
$38.57 /

+0.96 (+2.55%)

NVTA Invitae
$37.65 /

-1.47 (-3.76%)

NVS Novartis
$88.02 /

+0.81 (+0.93%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

HZNP Horizon Therapeutics
$93.25 /

-0.32 (-0.34%)

DGX Quest Diagnostics
$130.09 /

+0.86 (+0.67%)

CPRX Catalyst Pharmaceuticals
$4.44 /

-0.02 (-0.45%)

BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

BIIB Biogen
$270.07 /

-0.66 (-0.24%)

BHVN Biohaven Pharmaceutical
$74.37 /

-1.435 (-1.89%)

AVDL Avadel Pharmaceuticals
$8.65 /

+0.09 (+1.05%)

ACAD Acadia Pharmaceuticals
$21.17 /

-0.02 (-0.09%)

ABT Abbott
$124.37 /

+0.4 (+0.32%)

ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

ZGNX Zogenix
$19.00 /

-0.65 (-3.31%)

TGTX TG Therapeutics
$44.79 /

-1.05 (-2.29%)

TEVA Teva
$10.75 /

-0.08 (-0.74%)

TAK Takeda Pharmaceutical
$17.08 /

-0.13 (-0.76%)

PFE Pfizer
$38.57 /

+0.96 (+2.55%)

NVTA Invitae
$37.65 /

-1.47 (-3.76%)

MDT Medtronic
$125.91 /

+0.06 (+0.05%)

LLY Eli Lilly
$189.25 /

+3.28 (+1.76%)

JNJ Johnson & Johnson
$162.24 /

+1.74 (+1.08%)

HZNP Horizon Therapeutics
$93.25 /

-0.32 (-0.34%)

DGX Quest Diagnostics
$130.09 /

+0.86 (+0.67%)

BMY Bristol-Myers
$65.46 /

+1.02 (+1.58%)

BIIB Biogen
$270.07 /

-0.66 (-0.24%)

ABT Abbott
$124.37 /

+0.4 (+0.32%)

ABC AmerisourceBergen
$119.62 /

+0.55 (+0.46%)

ABBV AbbVie
$107.93 /

+1.05 (+0.98%)

Conference/Events
Alnylam to host conference call » 04:55
04/19/21
04/19
04:55
04/19/21
04:55
ALNY

Alnylam

$138.69 /

-0.23 (-0.17%)

Management holds a…

Management holds a conference call to discuss the full 9-month results from the HELIOS-A Phase 3 clinical trial on April 19 at 4 pm. Webcast Link

ShowHide Related Items >><<
ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

ALNY Alnylam
$138.69 /

-0.23 (-0.17%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.